FDA approves biosimilar to bevacizumabSeptember 14, 2017GastroenterologyLung CancerGynecologic CancerCNS/Brain CancerRenal Cell CarcinomaNeuro-oncologyGastrointestinal Cancer
PROTECT trial: No DFS benefit with adjuvant pazopanib for high-risk RCCSeptember 14, 2017Renal Cell CarcinomaGenitourinary Cancer
Pembrolizumab, nivolumab linked to 3% rate of neurologic eventsSeptember 5, 2017Immuno-oncologyPatient & Survivor CareMelanomaLung CancerRenal Cell CarcinomaHead & Neck/Thyroid CancersNeuro-oncology
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic reviewAugust 28, 2017Immuno-oncologyImmunotherapyMelanomaRenal Cell CarcinomaLung Cancer
FDA advisory committee to consider adjuvant sunitinib for RCCAugust 16, 2017Renal Cell CarcinomaGenitourinary Cancer
Sequential pazopanib and everolimus nets good survival in metastatic RCCAugust 8, 2017Renal Cell CarcinomaGenitourinary Cancer
No survival benefit with adjuvant girentuximab in high-risk RCCJuly 19, 2017Renal Cell CarcinomaGenitourinary Cancer
Savolitinib improves PFS in some with MET-driven papillary renal cell carcinomaJuly 6, 2017Renal Cell CarcinomaGenitourinary Cancer
PROTECT: Pazopanib falls short as adjuvant therapy for high-risk RCCJune 19, 2017Renal Cell CarcinomaGenitourinary Cancer
Immune-agonist combo has activity against several tumor typesJune 5, 2017Immuno-oncologyImmunotherapyBreast CancerMelanomaRenal Cell CarcinomaGynecologic CancerGenitourinary Cancer
Alternating therapy in renal cell carcinoma fails to show an advantageMay 17, 2017Renal Cell CarcinomaGenitourinary Cancer
Debulking called reasonable for unresectable liver cancerApril 14, 2017Renal Cell CarcinomaGastroenterologyGastrointestinal Cancer
